QUANTITATIVE RENAL HYPERPOLARIZED [1-13C]PYRUVATE PERFUSION AND METABOLIC IMAGING IN DIABETIC KIDNEY DISEASE

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508824-36-00

Enrollment

Registered

2024-02-29

Start date

2024-09-24

Completion date

Unknown

Last updated

2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Brief summary

Metabolism and perfusion of kidney by hyperpolarised pyruvate

Detailed description

Glomerular Filtration Rate (Renography), reproducibility of hyperpolarised pyruvate MRI

Interventions

DRUGHyperpolarized [1-13C]pyruvate

DRUGGADOTERIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Metabolism and perfusion of kidney by hyperpolarised pyruvate	—

Secondary

Measure	Time frame
Glomerular Filtration Rate (Renography), reproducibility of hyperpolarised pyruvate MRI	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026